Dr. Ammira Akil

Director and Lead Principal Investigator, Sidra Medicine

Dr. Ammira A.S. Akil is a visionary healthcare leader and genomics strategist with a proven ability to drive large-scale innovation, commercialize cutting-edge science, contributing to build sustainable healthcare ecosystems. As a Principal Investigator and Director of Translational Mendelian and Metabolic Clinical Genomics Program at Sidra Medicine, she spearheads initiatives that bridge genomic research, clinical adoption, and scalable health tech solutions, positioning Qatar as a global leader in precision medicine.

With a PhD in Molecular Biology and Genetics and an Executive MBA from HEC Paris (specializing in Entrepreneurship & Innovation), Dr. Akil combines deep scientific expertise with business acumen and strategic leadership. She has played a pivotal role in shaping Qatar’s national genomics agenda, securing cross-sector partnerships, and advancing population-scale precision health programs with long-term economic and clinical impact.

A sought-after advisor and mentor, Dr. Akil actively fosters the next generation of healthcare entrepreneurs. As Chair of the Precision Medicine and the Future of Genomics (PMFG) Summit, she convenes global leaders to accelerate investment, policy, and commercialization in genomics and digital health. Through her work with national accelerators, she guides startups in product-market fit, regulatory strategy, and scalable business models, ensuring innovations translate into real-world healthcare solutions.

Recognized for her executive leadership in multidisciplinary teams, Dr. Akil excels at translating complex science into actionable business strategies. Her work is driven by a mission to build resilient, patient-centric health systems while positioning the region as a hub for genomic innovation and entrepreneurial growth.